Vibrant Capsule vs. Placebo for Patient Suffering From Constipation

Exclusion Criteria

• •1. History of complicated/obstructive diverticular disease
• •2. History of intestinal or colonic obstruction, or suspected intestinal obstruction.
• •3. History of significant gastrointestinal disorder, including any form of inflammatory bowel disease or gastrointestinal malignancy (celiac disease is accepted if the subject has been treated and is in remission)
• •4. Clinical evidence of current and significant gastroparesis
• •5. Use of any of the following medications:
• •* Medications that may affect intestinal motility (including but not limited to prokinetics, anti-Parkinsonian medications, opiates, opioids, Verapamil, Nifedipine, iron, magnesium supplements, Tricyclic antidepressants (TCAs), Heparin, Warfarin and Baclofen.
• •* With the exception of antidepressants (other than TCAs), thyroid or hormonal replacement therapy, when the subject has been on a stable dose for at least 3 months prior to enrollment.
• •6. Clinical evidence of significant respiratory, cardiovascular, renal, hepatic, biliary, endocrine, psychiatric or neurologic disease.
• •7. Presence of cardiac pacemaker, gastric electrical stimulator or any electrical implanted device.
• •8. History of, or current eating disorders, such as anorexia, bulimia, or compulsory overeating.
• •9. Diagnosis of mega-rectum or colon, congenital anorectal malformation, clinically significant rectocele, history of intestinal resection (with an exception for appendectomy, cholecystectomy and inguinal hernia repair), history of bariatric surgery or evidence of any structural abnormality of the gastrointestinal tract that might affect capsule's transit
• •10. History of Zenker's diverticulum, dysphagia, esophageal stricture, eosinophilic esophagitis or achalasia
• •11. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs): chronic use is defined as taking full dose NSAIDs more than three times a week for at least six months. Subjects on cardiac doses of aspirin may be enrolled in the study
• •12. Subjects with pelvic floor dysfunction/defecatory disorder, based on subject history
• •13. Participation in another interventional clinical study within one month prior to screening.
• •14. Women who are pregnant or lactating
• •15. Use of any medication for constipation relief during the study, except as rescue medication, as indicated by study rules
• •16. Inability to use an electronic daily Diary (on a computer, phone application, tablet or other electronic device) to report bowel movements, symptoms and medication usage
• •17. Subject participated in a previous Vibrant study
• •18. Subjects planning to undergo MRI during the study
• •19. Any known allergy to soybean, beeswax, Calcium Carbonate, Gelatin, Glycerin or Titanium dioxide
• •20. Any other condition which in the opinion of the investigator may adversely affect the safety of the subject or would limit the subject's ability to complete the study